The incidence of adverse reactions is classified as follows: very often (≥ 1/10); often (from ≥ 1/100 to <1/10); infrequently (from ≥ 1/1000 to <1/100), rarely (from ≥ 1/10000 to <1/1000); very rarely (<1/10000).
Often: "tides" from medium to severe severity and hyperhidrosis, which usually do not require discontinuation of treatment.
Very often at the beginning of treatment: In the treatment of infertility, the combination with gonadotropins can lead to a syndrome of ovarian hyperstimulation. In this case, there is an increase in the size of the ovaries, dyspnea, pelvic pain and / or abdominal pain.
During treatment There are also side effects such as: muscle pain, vomiting, increased blood pressure, increased activity of "hepatic" enzymes.
Very often at the beginning of Dipherylin treatment, 3.75 mg and 11.25 mg: bleeding from the vagina, including the development of heavy bleeding during menstruation or in the intermenstrual period one month after the first injection.
Very often during treatment with Dipherylin 3.75 mg and 11.25 mg: peripheral edema, paresthesia, adverse reactions related to the general picture of hypoestrogenic phenomena associated with blockade of the pituitary-egg system, such as sleep disorders, headache,emotional lability, dryness of the vaginal mucosa and dyspareunia, decreased libido.
Often during treatment with Dipherylin 3.75 mg: pain in the mammary glands, muscle spasm, joint pain, weight gain, nausea, abdominal pain / discomfort, asthenia.
Local tolerance
Very rarely: pain, erythema and inflammation at the injection site.
Post-registration application experience
During post-registration follow-up, additional adverse events were reported in the preparation of women for IVF. Side effects are classified according to the systemic organ class and in descending order of the frequency of the phenomena:
Disturbances from the skin and subcutaneous tissues: reactions Hypersensitivity, including itching, urticaria, rash, swelling of Quincke.
Impaired nervous system: headache
Disorders from the side of the organ of vision: episodes of blurred vision or visual impairment.
Long-term use (more than 6 months) of GnRH analogues can lead to demineralization of bones, a risk of osteoporosis. The above-described side effect was not observed with the use of the preparation Diperelin® 0.1 mg; therapy does not involve long-term treatment.
Reported changes in mood, including depression on the background of the drug.